Compositions and methods relating to reduction of symptoms of autism
First Claim
1. A composition for reducing symptoms of autism in a human patient comprising a physiologically effective amount of a purified casomorphinase which is a dipeptidyl peptidase, a physiologically effective amount of a purified gluteomorphinase which is a tyrosinase or a phenylalaninase, and at least one of the group consisting of a physiologically acceptable carrier, an adjuvant, an excipient, a buffer and a diluent, wherein the composition is capable of decreasing the incidence of one or more symptoms consisting of eye contact avoidance, failure to socialize, attention deficit, poor mood, hyperactivity, anxiety, stimming, poor comprehension, inappropriate speech, abnormal sound sensitivity, poor digestion, disrupted sleep, and perseveration, and wherein the composition is suitable for oral administration and the decreased incidence is measured relative to the incidence of said one or more symptoms in the untreated individual.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, to a human patient in sufficient quantities to reduce the effects of the autism. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.
-
Citations
23 Claims
- 1. A composition for reducing symptoms of autism in a human patient comprising a physiologically effective amount of a purified casomorphinase which is a dipeptidyl peptidase, a physiologically effective amount of a purified gluteomorphinase which is a tyrosinase or a phenylalaninase, and at least one of the group consisting of a physiologically acceptable carrier, an adjuvant, an excipient, a buffer and a diluent, wherein the composition is capable of decreasing the incidence of one or more symptoms consisting of eye contact avoidance, failure to socialize, attention deficit, poor mood, hyperactivity, anxiety, stimming, poor comprehension, inappropriate speech, abnormal sound sensitivity, poor digestion, disrupted sleep, and perseveration, and wherein the composition is suitable for oral administration and the decreased incidence is measured relative to the incidence of said one or more symptoms in the untreated individual.
- 9. A method for reducing symptoms of autism in a human patient, comprising orally administering to the patient a composition comprising a physiologically effective amount of a purified casomorphinase which is a dipeptidyl peptidase, a physiologically effective amount of a purified gluteomorphinase which is a tyrosinase or a phenylalaninase, and at least one of the group consisting of a physiologically acceptable carrier, an adjuvant, an excipient, a buffer and a diluent, wherein the composition is capable of decreasing the incidence of one or more symptoms consisting of eye contact avoidance, failure to socialize, attention deficit, poor mood, hyperactivity, anxiety, stimming, poor comprehension, inappropriate speech, abnormal sound sensitivity, poor digestion, disrupted sleep, and perseveration, and wherein the composition is suitable for oral administration and the decreased incidence is measured relative to the incidence of said one or more symptoms in the untreated individual.
-
21. A method of manufacturing a medicament for reducing symptoms of autism in a human patient, comprising combining a physiologically effective amount of a purified casomorphinase which is a dipeptidyl peptidase, a physiologically effective amount of a purified gluteomorphinase which is a tyrosinase or a phenylalaninase, and at least one of the group consisting of a physiologically acceptable carrier, an adjuvant, an excipient, a buffer and a diluent, wherein the composition is capable of decreasing the incidence of one or more symptoms consisting of eye contact avoidance, failure to socialize, attention deficit, poor mood, hyperactivity, anxiety, stimming, poor comprehension, inappropriate speech, abnormal sound sensitivity, poor digestion, disrupted sleep, and perseveration, and wherein the composition is suitable for oral administration and the decreased incidence is measured relative to the incidence of said one or more symptoms in the untreated individual.
Specification